Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sanofi Allegra Switch Approval Triggers Race To Market For Perrigo

This article was originally published in The Tan Sheet

Executive Summary

Sanofi-Aventis will launch nonprescription Allegra allergy relief products March 4, but the line might not beat private-label fexofenadine products to store shelves.

You may also be interested in...



Digital Revolution Will Not Be Free: Facilitating OTC Switches, Engaging Consumers

Digital technologies could transform how consumers shop for OTC drugs in stores, but costs could be significant, say industry consultants. Marketers are looking to create digital “touch points” such as interactive kiosks to create two-way communication between brands and customers.

Digital Revolution Will Not Be Free: Facilitating OTC Switches, Engaging Consumers

Digital technologies could transform how consumers shop for OTC drugs in stores, but costs could be significant, say industry consultants. Marketers are looking to create digital “touch points” such as interactive kiosks to create two-way communication between brands and customers.

Allegra-D Joins ‘Common Cold’ Club In OTC Antihistamine Market

Allegra-D has competed in the OTC antihistamine space without including “relief of nasal congestion due to the common cold” in its indications since its 2011 launch through Sanofi’s Chattem business.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS104835

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel